Amylyx Centaur AMX0035 Trial Results
Time & Location
About the Event
We are excited to host our next EverythingALS Patient Community Meeting: Amylyx Centaur AMX0035 Trial Results.
We invite you to join us and other ALS patients and families to engage in a positive setting of collaboration and community.
The meeting will be Wednesday, November 9th at 4:00 pm PDT
-5:00pm Mountain Time
-6:00pm Central Time
-7:00pm Eastern Time
The meeting will be approximately 30-45mins long followed by an open forum.
Once you RSVP the Zoom details with password will be sent via email. Watch out for the email.
If you have any questions please email us at email@example.com
Our Guest Speakers, Dr. Merit Cudkowicz and Dr. Sabrina Paganoni are the principal investigators at the HEALEY ALS Platform Trial. Will be discussing the results of Amylyx's ALS Drug which shows promise in Phase II/III Clinical Trials.
Dr. Merit Cudkowicz is the Director of the Healey Center for ALS, Chief of Neurology at at Mass General Hospital and the Julieanne Dorn Professor of Neurology at HMS. She is dedicated to the study and treatment of people with ALS. As Principal Investigator of the Clinical Coordination Center for the National Institute of Neurological Disorders and Stroke’s Neurology Network of Excellence in Clinical Trials (NeuroNEXT), Dr. Cudkowicz mentors many neurologists in clinical investigation of neurological disorders.
She completed her undergraduate degree in chemical engineering at MIT and earned a medical degree at HMS. She completed her neurology residency and fellowship at MGH.
Dr. Sabrina Paganoni, MD, PhD is a physician investigator at the Healey Center for ALS at Mass General, Co-Director of the Neurological Research Institute at the Massachusetts General Hospital and Assistant Professor of Physical Medicine and Rehabilitation at Harvard Medical School. Dr. Paganoni obtained her MD degree at the University of Milan in Italy and a PhD in Neuroscience at Northwestern University. She is Board-certified in Physical Medicine and Rehabilitation, Neuromuscular Medicine, and Electrodiagnostic Medicine. She has served as the Principal Investigator of many ALS clinical trials and has been using novel neuroimaging techniques, bio-fluid biomarkers and digital technology as measures of target engagement in these trials. Currently, she is the co-Principal Investigator of the HEALEY ALS Platform Trial.
We look forward to seeing you at the event!